why choose us

First received: April 04, 2023

Clinical Trial: Ladarixin With Sotorasib in Advanced NSCLC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Study Type: INTERVENTIONAL


Official Title: Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

Brief Summary: This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).

Read more